title: Gene-environment interactions of selected pharmacogenes in arterial hypertension.
abstract: Hypertension affects approximately 1 billion people worldwide. Owing to population aging, hypertension-related cardiovascular burden is expected to rise in the near future. In addition to genetic variants influencing the blood pressure response to antihypertensive drugs, several genes encoding for drug-metabolizing or -transporting enzymes have been associated with blood pressure and/or hypertension in humans (e.g., ACE, CYP1A2, CYP3A5, ABCB1 and MTHFR) regardless of drug treatment. These genes are also involved in the metabolism and transport of endogenous substances and their effects may be modified by selected environmental factors, such as diet or lifestyle. However, little is currently known on the complex interplay between environmental factors, endogenous factors, genetic variants and drugs on blood pressure control. This review will discuss the respective role of population-based primary prevention and personalized medicine for arterial hypertension, taking a pharmacogenomics' perspective focusing on selected pharmacogenes.
authors.affiliation: Institute of Social and Preventive Medicine, Lausanne University Hospital, Switzerland. murielle.bochud@chuv.ch
authors.forename: Murielle
authors.initials: M
authors.lastname: Bochud
authors.forename: Idris
authors.initials: I
authors.lastname: Guessous
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects / Q000235:genetics; D059647:Gene-Environment Interaction; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000235:genetics; D008019:Life Style; D010597:Pharmacogenetics; D010641:Phenotype; D011110:Polymorphism, Genetic
chemical_list: D000959:Antihypertensive Agents